| Abstract: |
Oligodendrogliomas account for a small subset of all gliomas, but they often are more sensitive to treatment than other glioma subtypes. In addition, oligodendrogliomas are the first central nervous system neoplasm for which a specific molecular abnormality, allelic loss of 1p/19q (1p/19q loss), correlates with patient outcome in large-scale prospective clinical trials. However, the incorporation of 1p/19q status into clinical practice remains controversial. Other molecular alterations found in oligodendrogliomas include hypermethylation of the promoter for the MGMT gene, TP53 mutations, EGFR and platelet-derived growth factor/PDGFR alterations, and 9p and 10q loss. |
| Keywords: |
platelet derived growth factor; genetics; mutation; review; brain tumor; brain neoplasms; chromosome 1; chromosome 19; metabolism; allele; epidermal growth factor receptor; alleles; receptor, epidermal growth factor; platelet derived growth factor receptor; protein p53; dna methylation; tumor suppressor gene; platelet-derived growth factor; tumor suppressor protein p53; chromosomes, human, pair 19; oligodendroglioma; chromosome deletion; chromosomes, human, pair 1; tp53 protein, human; receptors, platelet-derived growth factor; genes, p53; chromosome map; chromosome mapping
|
